E-DRUG: Access to Medicine Index 2012 Launched
---------------------------------------------
Today, the Access to Medicine Index 2012 was launched and is available for
download at www.accesstomedicineindex.org.
The latest Access to Medicine Index, which ranks the top 20 pharmaceutical
companies on their efforts to improve access to medicine in developing
countries, finds that the industry is doing more than it was two years ago,
with GlaxoSmithKline still outperforming its peers, but an expanding group
of leaders closing the gap.
However, there are still several areas where all companies could improve
their approaches significantly. These include being more transparent about
their lobbying practices, expanding their tiered pricing schemes, adapting
packaging to local needs, making their drug donations more needs-based, and
allowing their clinical trial data to be used to accelerate the approval of
generic medicines in developing countries.
The aim of the Access to Medicine Index is to stimulate positive change by
publicly encouraging pharmaceutical companies to step up their efforts as
part of the global health community's endeavours to improve access to
medicine worldwide. The scoring and ranking of company performance for the
2012 Index was conducted by MSCI ESG Research.
More findings are available in the full report at
www.accesstomedicineindex.org.
Regards,
--
Sara Brewer
Research
Access to Medicine Foundation
Scheepmakersdijk 5A, 2011 AS Haarlem
The Netherlands
Phone: +31.23.533.9187
Mobile: +31.64.212.1622
www.atmindex.org